Skip to main content

Conmed Value Stock - Dividend - Research Selection

Conmed

ISIN: US2074101013 , WKN: 886793

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. It offers orthopedic surgery products under Hall, CONMED Linvatec, Concept, and Shutt brands. The company also offers general surgery product in the areas of advanced surgical comprising clinical insufflation system; electrosurgical products; endomechanical products comprising instruments, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors; and uterine manipulator (VCARE) for use in increasing the efficiency of laparoscopic hysterectomies and other gynecologic laparoscopic procedures. In addition, it offers general surgery product in the areas of endoscopic technologies, including minimally invasive diagnostic and therapeutic products; critical care products cover a line of vital signs, cardiac monitoring, and patient care products, including ECG electrodes and accessories, cardiac defibrillation and pacing pads, and suction instruments and tubing; and physician\'s office electrosurgical product used by dermatologists. The company\'s products are used by surgeons and physicians in orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. CONMED Corporation was founded in 1970 and is headquartered in Utica, New York.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Here's Why You Should Retain CONMED Stock in Your Portfolio for Now

2026-02-10
CNMD's growth rests on AirSeal, Buffalo Filter and BioBrace as supply chains normalize, even as tariffs and a GI exit pressure EPS.

5 Must-Read Analyst Questions From CONMED’s Q4 Earnings Call

2026-02-04
CONMED’s fourth-quarter results were well received by the market, driven by standout performance in its orthopedics portfolio and continued progress in resolving supply chain challenges. Management highlighted the company’s exit from lower-growth gastroenterology product lines and renewed focus on high-growth areas such as robotic and laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair. CEO Patrick Beyer credited improvements in sports medicine supply, successful launches l

[Latest] Global Advanced Wound Closure Market Size/Share Worth USD 32.54 Billion by 2035 at a 6.9% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

2026-02-02
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Advanced Wound Closure Market size & share revenue was valued at approximately USD 18.47 Billion in 2025 and is expected to reach USD 19.68 Billion in 2026 and is expected to reach around USD 32.54 Billion by 2035, at a CAGR of 6.9% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Johnson & Johnson (Ethi

Assessing CONMED (CNMD) Valuation After Q4 Results And Surgical Portfolio Shift

2026-02-02
Q4 earnings and 2026 outlook reframe the CONMED (CNMD) story CONMED (CNMD) just reported Q4 2025 results that paired higher sales with weaker profitability, while also laying out 2026 revenue guidance and a clear shift away from lower-growth gastroenterology products. See our latest analysis for CONMED. The Q4 update and 2026 revenue outlook arrive after a tough stretch for shareholders, with a 1 year total shareholder return of 45.9% and a 5 year total shareholder return of 64.7%. The 90 day...

1 Cash-Producing Stock to Target This Week and 2 We Find Risky

2026-02-02
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

CONMED Stock Up Post Q4 Earnings and Revenue Beat, Gross Margin Up

2026-01-29
CNMD posts strong fourth-quarter 2025 results with EPS and revenue beat, driven by surgical growth and improved gross margin.

Wells Fargo Maintains Equal-Weight on Conmed, Raises Price Target to $42

2026-01-29
Wells Fargo analyst Vik Chopra maintains Conmed (NYSE:CNMD) with a Equal-Weight and raises the price target from $41 to $42.

What Analysts Are Saying About Conmed Stock

2026-01-29

Needham Reiterates Hold on Conmedto Hold

2026-01-29
Needham analyst Mike Matson reiterates Conmed (NYSE:CNMD) from Hold to Hold.

CNMD Q4 Deep Dive: Ortho Outperformance and Strategic Refocusing Shape 2026 Outlook

2026-01-29
Medical tech company CONMED (NYSE:CNMD) announced better-than-expected revenue in Q4 CY2025, with sales up 7.9% year on year to $373.2 million. On the other hand, the company’s full-year revenue guidance of $1.36 billion at the midpoint came in 0.7% below analysts’ estimates. Its non-GAAP profit of $1.43 per share was 8% above analysts’ consensus estimates.